No Data
No Data
Youcare Pharmaceutical Gets US FDA Green Light For Lower Respiratory Tract Disease Vaccine Trial
Youcare Pharmaceutical Group (688658.SH): Subsidiary YKYY025 injection has received FDA clinical trial approval.
On January 10, Gelonghui reported that Youcare Pharmaceutical Group (688658.SH) announced that its wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. (referred to as 'Hangzhou Tianlong') recently received a notification from the USA Food and Drug Administration (referred to as 'FDA') regarding the approval of clinical trials for the YKYY025 injection for the prevention of lower respiratory tract diseases caused by respiratory syncytial virus (RSV) (Study May Proceed Letter, IND number: 31233). The YKYY025 injection is an independently developed product by Hangzhou Tianlong that encodes the respiratory syncytial virus.
Youcare Pharmaceutical Group (688658.SH): Applying for optimization and adjustment of the product price for ginkgo leaf extract injection in response to the concerns raised in the "attention letter."
On December 30, Gelonghui reported that Youcare Pharmaceutical Group (688658.SH) announced that it had noted the letter from the National Healthcare Security Administration's office regarding concerns about certain pharmaceutical companies issuing false invoices to create 'dual pricing', which has attracted widespread attention in the market. The 'Concern Letter' involves the company's product 'Ginkgo Biloba Extract Injection'. The company and the Board of Directors promptly organized relevant personnel to verify the specifics of the matter, and now provide the following explanation: 1. In response to the issues in the 'Concern Letter', the company took the initiative to communicate with the local healthcare security bureau, applying to optimize and adjust the production of Ginkgo Biloba Extract Injection.
Youcare Pharmaceutical Group Co., Ltd. (SHSE:688658) Might Not Be As Mispriced As It Looks After Plunging 27%
Youcare Pharmaceutical Group to Terminate Coding System Project
Youcare Pharmaceutical Group (688658.SH): plans to use the remaining raised surplus funds of 38.4278 million yuan to permanently supplement working capital.
On December 18, Gelonghui reported that Youcare Pharmaceutical Group (688658.SH) announced that it will hold the 17th meeting of the second Board of Directors and the 15th meeting of the second Supervisory Board on December 18, 2024. The meetings reviewed and approved the proposal on the permanent supplement of working capital using the remaining excess fundraising. The company agreed to use the remaining excess fundraising of 38.4278 million yuan (including interest and cash management income, with the specific amount based on the actual amount at the time of transfer) to permanently supplement working capital, which accounts for 7.50% of the total excess fundraising.